Low-PRISMNCT06482489
Accurate Prostate Cancer Following Using Low-Field MRI (Low-PRISM)
At risk: Primary completion moved 2 years later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion dates pushed to May 31, 2027
- Eligibility criteria expanded, about 17 words
- Publications: details revised at 6 of 6 entries
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Aug 1, 2024 to Nov 1, 2024
- Study sites: 0 to 1
- Minor Study description revisedv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (2)
Arms and interventions
The commencement of the study involves the formulation of the 0.55T MRI protocol. For this purpose, a cohort of 23 male volunteers will undergo a 0.55T MRI. The objective is to achieve the same spatial resolution and coverage as observed at 3T.
The second phase of the research will be carried out to compare the MRI image quality between 0.55T and 3T MRI. The study will involve 20 adult men, who on 3T prostate MRI, have DWI reported as sub-diagnostic (PI-QUAL \< 3) due to the presence of metallic implant(s).
The third phase includes 31 patients whose 3T MRIs detected lesions classified as PI-RADS 4/5 and who are scheduled for targeted prostate biopsy.
Devices: Siemens Magnetom Free.Max 0.55T (Siemens Healthineers, Erlangen, Germany).
Sites
1 site in 1 country
- Lausanne University HospitalLausanne, Canton of Vaud, Switzerland